Which has better valuation & earnings, CNTA or AAPG?

Ascentage Pharma Group International has higher revenue and earnings than Centessa Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Centessa Pharmaceuticals $15M 419.94 -$197.53M -$1.79 N/A Ascentage Pharma Group International $82.10M 19.43 -$177.71M N/A N/A

Is CNTA or AAPG more profitable?

Ascentage Pharma Group International's return on equity of 0.00% beat Centessa Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Centessa Pharmaceuticals N/A -60.37% -44.17% Ascentage Pharma Group International N/A N/A N/A

Which has higher earnings and valuation, RGC or AAPG?

Regencell Bioscience has higher earnings, but lower revenue than Ascentage Pharma Group International. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Regencell Bioscience N/A N/A -$3.58M N/A N/A Ascentage Pharma Group International $82.10M 19.43 -$177.71M N/A N/A

Is RGC or AAPG more profitable?

Company Net Margins Return on Equity Return on Assets Regencell Bioscience N/A N/A N/A Ascentage Pharma Group International N/A N/A N/A

Which has stronger earnings & valuation, AAPG or COGT?

Ascentage Pharma Group International has higher revenue and earnings than Cogent Biosciences. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Ascentage Pharma Group International $82.10M 19.43 -$177.71M N/A N/A Cogent Biosciences N/A N/A -$328.94M -$2.17 N/A

Is AAPG or COGT more profitable?

Ascentage Pharma Group International's return on equity of 0.00% beat Cogent Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Ascentage Pharma Group International N/A N/A N/A Cogent Biosciences N/A -104.27% -54.64%

Which has stronger valuation and earnings, BLTE or AAPG?

Belite Bio has higher earnings, but lower revenue than Ascentage Pharma Group International. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Belite Bio N/A N/A -$77.61M -$2.53 N/A Ascentage Pharma Group International $82.10M 19.43 -$177.71M N/A N/A

Is BLTE or AAPG more profitable?

Ascentage Pharma Group International's return on equity of 0.00% beat Belite Bio's return on equity. Company Net Margins Return on Equity Return on Assets Belite Bio N/A -13.14% -12.88% Ascentage Pharma Group International N/A N/A N/A

Which has better earnings & valuation, AAPG or SRRK?

Ascentage Pharma Group International has higher revenue and earnings than Scholar Rock. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Ascentage Pharma Group International $82.10M 19.43 -$177.71M N/A N/A Scholar Rock N/A N/A -$377.94M -$3.59 N/A

Is AAPG or SRRK more profitable?

Ascentage Pharma Group International's return on equity of 0.00% beat Scholar Rock's return on equity. Company Net Margins Return on Equity Return on Assets Ascentage Pharma Group International N/A N/A N/A Scholar Rock N/A -163.52% -96.67%

Ascentage Pharma Group International (AAPG) Competitors

$17.08 +0.07 (+0.41%)

Closing price 06/24/2026 03:54 PM Eastern

Extended Trading

$17.14 +0.07 (+0.38%)

As of 04:09 AM Eastern

Compare

AAPG vs. CNTA, RGC, COGT, BLTE, and SRRK

Should you buy Ascentage Pharma Group International stock or one of its competitors? MarketBeat compares Ascentage Pharma Group International with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Ascentage Pharma Group International include Centessa Pharmaceuticals (CNTA), Regencell Bioscience (RGC), Cogent Biosciences (COGT), Belite Bio (BLTE), and Scholar Rock (SRRK). These companies are all part of the "pharmaceutical products" industry.

How does Ascentage Pharma Group International compare to Centessa Pharmaceuticals?

Centessa Pharmaceuticals (NASDAQ:CNTA) and Ascentage Pharma Group International (NASDAQ:AAPG) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, media sentiment, risk, institutional ownership, earnings, profitability, valuation and analyst recommendations.

Ascentage Pharma Group International's return on equity of 0.00% beat Centessa Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Centessa Pharmaceuticals	N/A	-60.37%	-44.17%
Ascentage Pharma Group International	N/A	N/A	N/A

Ascentage Pharma Group International has higher revenue and earnings than Centessa Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Centessa Pharmaceuticals	$15M	419.94	-$197.53M	-$1.79	N/A
Ascentage Pharma Group International	$82.10M	19.43	-$177.71M	N/A	N/A

Centessa Pharmaceuticals has a beta of 1.11, suggesting that its stock price is 11% more volatile than the broader market. Comparatively, Ascentage Pharma Group International has a beta of -0.05, suggesting that its stock price is 105% less volatile than the broader market.

82.0% of Centessa Pharmaceuticals shares are held by institutional investors. 4.1% of Centessa Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Centessa Pharmaceuticals currently has a consensus target price of $41.33, indicating a potential upside of 1.53%. Ascentage Pharma Group International has a consensus target price of $46.43, indicating a potential upside of 171.83%. Given Ascentage Pharma Group International's stronger consensus rating and higher possible upside, analysts plainly believe Ascentage Pharma Group International is more favorable than Centessa Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Centessa Pharmaceuticals	1 Sell rating(s)	9 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.21
Ascentage Pharma Group International	0 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	3.20

In the previous week, Centessa Pharmaceuticals had 3 more articles in the media than Ascentage Pharma Group International. MarketBeat recorded 3 mentions for Centessa Pharmaceuticals and 0 mentions for Ascentage Pharma Group International. Centessa Pharmaceuticals' average media sentiment score of 0.54 beat Ascentage Pharma Group International's score of 0.00 indicating that Centessa Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Centessa Pharmaceuticals	Positive
Ascentage Pharma Group International	Neutral

Summary

Ascentage Pharma Group International beats Centessa Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

How does Ascentage Pharma Group International compare to Regencell Bioscience?

Regencell Bioscience (NASDAQ:RGC) and Ascentage Pharma Group International (NASDAQ:AAPG) are both pharmaceutical products companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, valuation, institutional ownership, earnings, media sentiment, dividends, profitability and analyst recommendations.

Ascentage Pharma Group International has a consensus price target of $46.43, indicating a potential upside of 171.83%. Given Ascentage Pharma Group International's stronger consensus rating and higher probable upside, analysts clearly believe Ascentage Pharma Group International is more favorable than Regencell Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Regencell Bioscience	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Ascentage Pharma Group International	0 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	3.20

In the previous week, Regencell Bioscience had 18 more articles in the media than Ascentage Pharma Group International. MarketBeat recorded 18 mentions for Regencell Bioscience and 0 mentions for Ascentage Pharma Group International. Regencell Bioscience's average media sentiment score of 0.00 beat Ascentage Pharma Group International's score of 0.00 indicating that Regencell Bioscience is being referred to more favorably in the media.

Company	Overall Sentiment
Regencell Bioscience	Neutral
Ascentage Pharma Group International	Neutral

Regencell Bioscience has a beta of 1.65, meaning that its stock price is 65% more volatile than the broader market. Comparatively, Ascentage Pharma Group International has a beta of -0.05, meaning that its stock price is 105% less volatile than the broader market.

0.1% of Regencell Bioscience shares are held by institutional investors. 2.0% of Regencell Bioscience shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Company	Net Margins	Return on Equity	Return on Assets
Regencell Bioscience	N/A	N/A	N/A
Ascentage Pharma Group International	N/A	N/A	N/A

Regencell Bioscience has higher earnings, but lower revenue than Ascentage Pharma Group International.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Regencell Bioscience	N/A	N/A	-$3.58M	N/A	N/A
Ascentage Pharma Group International	$82.10M	19.43	-$177.71M	N/A	N/A

Summary

Regencell Bioscience beats Ascentage Pharma Group International on 6 of the 11 factors compared between the two stocks.

How does Ascentage Pharma Group International compare to Cogent Biosciences?

Ascentage Pharma Group International (NASDAQ:AAPG) and Cogent Biosciences (NASDAQ:COGT) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, risk, analyst recommendations, dividends, institutional ownership, valuation, earnings and profitability.

Ascentage Pharma Group International has a beta of -0.05, meaning that its share price is 105% less volatile than the broader market. Comparatively, Cogent Biosciences has a beta of 0.34, meaning that its share price is 66% less volatile than the broader market.

In the previous week, Cogent Biosciences had 2 more articles in the media than Ascentage Pharma Group International. MarketBeat recorded 2 mentions for Cogent Biosciences and 0 mentions for Ascentage Pharma Group International. Cogent Biosciences' average media sentiment score of 0.36 beat Ascentage Pharma Group International's score of 0.00 indicating that Cogent Biosciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Ascentage Pharma Group International	Neutral
Cogent Biosciences	Neutral

Ascentage Pharma Group International has higher revenue and earnings than Cogent Biosciences.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ascentage Pharma Group International	$82.10M	19.43	-$177.71M	N/A	N/A
Cogent Biosciences	N/A	N/A	-$328.94M	-$2.17	N/A

Ascentage Pharma Group International's return on equity of 0.00% beat Cogent Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ascentage Pharma Group International	N/A	N/A	N/A
Cogent Biosciences	N/A	-104.27%	-54.64%

Ascentage Pharma Group International presently has a consensus target price of $46.43, suggesting a potential upside of 171.83%. Cogent Biosciences has a consensus target price of $43.73, suggesting a potential upside of 16.51%. Given Ascentage Pharma Group International's stronger consensus rating and higher probable upside, equities analysts clearly believe Ascentage Pharma Group International is more favorable than Cogent Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ascentage Pharma Group International	0 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	3.20
Cogent Biosciences	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.86

Summary

Ascentage Pharma Group International beats Cogent Biosciences on 6 of the 10 factors compared between the two stocks.

How does Ascentage Pharma Group International compare to Belite Bio?

Belite Bio (NASDAQ:BLTE) and Ascentage Pharma Group International (NASDAQ:AAPG) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, risk, valuation, media sentiment, analyst recommendations, dividends and earnings.

Belite Bio currently has a consensus target price of $203.00, indicating a potential upside of 34.64%. Ascentage Pharma Group International has a consensus target price of $46.43, indicating a potential upside of 171.83%. Given Ascentage Pharma Group International's stronger consensus rating and higher possible upside, analysts plainly believe Ascentage Pharma Group International is more favorable than Belite Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Belite Bio	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Ascentage Pharma Group International	0 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	3.20

Belite Bio has higher earnings, but lower revenue than Ascentage Pharma Group International.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Belite Bio	N/A	N/A	-$77.61M	-$2.53	N/A
Ascentage Pharma Group International	$82.10M	19.43	-$177.71M	N/A	N/A

Belite Bio has a beta of -1.24, indicating that its share price is 224% less volatile than the broader market. Comparatively, Ascentage Pharma Group International has a beta of -0.05, indicating that its share price is 105% less volatile than the broader market.

In the previous week, Belite Bio had 4 more articles in the media than Ascentage Pharma Group International. MarketBeat recorded 4 mentions for Belite Bio and 0 mentions for Ascentage Pharma Group International. Belite Bio's average media sentiment score of 0.42 beat Ascentage Pharma Group International's score of 0.00 indicating that Belite Bio is being referred to more favorably in the media.

Company	Overall Sentiment
Belite Bio	Neutral
Ascentage Pharma Group International	Neutral

0.5% of Belite Bio shares are held by institutional investors. 13.3% of Belite Bio shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Ascentage Pharma Group International's return on equity of 0.00% beat Belite Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Belite Bio	N/A	-13.14%	-12.88%
Ascentage Pharma Group International	N/A	N/A	N/A

Summary

Ascentage Pharma Group International beats Belite Bio on 8 of the 13 factors compared between the two stocks.

How does Ascentage Pharma Group International compare to Scholar Rock?

Ascentage Pharma Group International (NASDAQ:AAPG) and Scholar Rock (NASDAQ:SRRK) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, institutional ownership, risk, dividends, analyst recommendations, earnings and valuation.

In the previous week, Scholar Rock had 3 more articles in the media than Ascentage Pharma Group International. MarketBeat recorded 3 mentions for Scholar Rock and 0 mentions for Ascentage Pharma Group International. Scholar Rock's average media sentiment score of 1.15 beat Ascentage Pharma Group International's score of 0.00 indicating that Scholar Rock is being referred to more favorably in the news media.

Company	Overall Sentiment
Ascentage Pharma Group International	Neutral
Scholar Rock	Positive

Ascentage Pharma Group International presently has a consensus price target of $46.43, indicating a potential upside of 171.83%. Scholar Rock has a consensus price target of $56.00, indicating a potential upside of 7.01%. Given Ascentage Pharma Group International's stronger consensus rating and higher probable upside, equities analysts clearly believe Ascentage Pharma Group International is more favorable than Scholar Rock.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ascentage Pharma Group International	0 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	3.20
Scholar Rock	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	4 Strong Buy rating(s)	3.12

Ascentage Pharma Group International has a beta of -0.05, indicating that its share price is 105% less volatile than the broader market. Comparatively, Scholar Rock has a beta of 0.69, indicating that its share price is 31% less volatile than the broader market.

Ascentage Pharma Group International's return on equity of 0.00% beat Scholar Rock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ascentage Pharma Group International	N/A	N/A	N/A
Scholar Rock	N/A	-163.52%	-96.67%

91.1% of Scholar Rock shares are held by institutional investors. 13.3% of Scholar Rock shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Ascentage Pharma Group International has higher revenue and earnings than Scholar Rock.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ascentage Pharma Group International	$82.10M	19.43	-$177.71M	N/A	N/A
Scholar Rock	N/A	N/A	-$377.94M	-$3.59	N/A

Summary

Scholar Rock beats Ascentage Pharma Group International on 7 of the 13 factors compared between the two stocks.

Get Ascentage Pharma Group International News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AAPG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AAPG vs. The Competition

Export

Metric	Ascentage Pharma Group International	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.59B	$3.49B	$6.74B	$12.32B
Dividend Yield	N/A	2.28%	2.68%	5.88%
P/E Ratio	N/A	20.50	25.14	23.95
Price / Sales	19.43	328.65	531.12	107.90
Price / Cash	N/A	130.96	45.29	53.76
Price / Book	8.37	8.26	10.77	6.41
Net Income	-$177.71M	$23.91M	$3.56B	$337.14M
7 Day Performance	-0.23%	2.12%	1.00%	-1.06%
1 Month Performance	-18.71%	2.40%	0.81%	0.49%
1 Year Performance	-57.29%	57.09%	30.27%	28.43%

Ascentage Pharma Group International Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AAPG Ascentage Pharma Group International	3.7997 of 5 stars	$17.08 +0.4%	$46.43 +171.8%	-57.0%	$1.59B	$82.10M	N/A	600
CNTA Centessa Pharmaceuticals	1.4192 of 5 stars	$40.02 flat	$41.33 +3.3%	+186.7%	$6.19B	$15M	N/A	200	High Trading Volume
RGC Regencell Bioscience	0.5211 of 5 stars	$12.01 flat	N/A	-62.7%	$5.94B	N/A	N/A	10	Gap Down High Trading Volume
COGT Cogent Biosciences	1.7707 of 5 stars	$34.54 flat	$43.73 +26.6%	+418.4%	$5.90B	N/A	N/A	80	High Trading Volume
BLTE Belite Bio	3.1287 of 5 stars	$146.12 flat	$203.00 +38.9%	+152.6%	$5.86B	N/A	N/A	10	Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AAPG) was last updated on 6/25/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Ascentage Pharma Group International (AAPG) Competitors

AAPG vs. CNTA, RGC, COGT, BLTE, and SRRK

How does Ascentage Pharma Group International compare to Centessa Pharmaceuticals?

Summary

How does Ascentage Pharma Group International compare to Regencell Bioscience?

Summary

How does Ascentage Pharma Group International compare to Cogent Biosciences?

Summary

How does Ascentage Pharma Group International compare to Belite Bio?

Summary

How does Ascentage Pharma Group International compare to Scholar Rock?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AAPG vs. The Competition

Ascentage Pharma Group International Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Ascentage Pharma Group International (AAPG) Competitors

AAPG vs. CNTA, RGC, COGT, BLTE, and SRRK

How does Ascentage Pharma Group International compare to Centessa Pharmaceuticals?

Is CNTA or AAPG more profitable?

Which has better valuation & earnings, CNTA or AAPG?

Which has more risk and volatility, CNTA or AAPG?

Do insiders & institutionals believe in CNTA or AAPG?

Do analysts prefer CNTA or AAPG?

Does the media refer more to CNTA or AAPG?

Summary

How does Ascentage Pharma Group International compare to Regencell Bioscience?

Do analysts prefer RGC or AAPG?

Does the media refer more to RGC or AAPG?

Which has more volatility and risk, RGC or AAPG?

Do institutionals and insiders believe in RGC or AAPG?

Is RGC or AAPG more profitable?

Which has higher earnings and valuation, RGC or AAPG?

Summary

How does Ascentage Pharma Group International compare to Cogent Biosciences?

Which has more volatility & risk, AAPG or COGT?

Does the media prefer AAPG or COGT?

Which has stronger earnings & valuation, AAPG or COGT?

Is AAPG or COGT more profitable?

Do analysts recommend AAPG or COGT?

Summary

How does Ascentage Pharma Group International compare to Belite Bio?

Do analysts recommend BLTE or AAPG?

Which has stronger valuation and earnings, BLTE or AAPG?

Which has more volatility & risk, BLTE or AAPG?

Does the media refer more to BLTE or AAPG?

Do insiders and institutionals believe in BLTE or AAPG?

Is BLTE or AAPG more profitable?

Summary

How does Ascentage Pharma Group International compare to Scholar Rock?

Does the media prefer AAPG or SRRK?

Do analysts recommend AAPG or SRRK?

Which has more volatility and risk, AAPG or SRRK?

Is AAPG or SRRK more profitable?

Do insiders & institutionals believe in AAPG or SRRK?

Which has better earnings & valuation, AAPG or SRRK?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AAPG vs. The Competition

Ascentage Pharma Group International Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools